PacBio Outlines Expected Commercial Performance for RS at AGBT as Users Talk About their Experience
February 08, 2011
PacBio Outlines Expected Commercial Performance for RS at AGBT as Users Talk About their Experience
At a conference workshop, PacBio reported on the performance of its system in seven early-access customer labs and said how it expects the instrument to perform at commercial launch in the second quarter.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Launch of PacBio RS Drives Q2 Revenue, but Investors Raise Concerns Over Pace of Uptake
August 9, 2011 / In Sequence - PacBio Demos Improved Chemistry with E. coli Outbreak Sequencing; Plans Q4 Upgrade for RS
July 12, 2011 / In Sequence - In 'Conservative' Estimate, Investment Firm Predicts PacBio Will Ship 46 Instruments in 2011
April 19, 2011 / In Sequence - PacBio Grows Order Backlog in Q4; Sees Increased Interest in Microbial Sequencing
February 22, 2011 / In Sequence - USPTO Board Rules on PacBio, Life Tech Patent Interference Case
February 1, 2011 / In Sequence